|Day Low/High||109.40 / 110.47|
|52 Wk Low/High||58.59 / 109.75|
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.
Celgene Corporation (NASDAQ: CELG) today announced data from nearly 70 Company-sponsored, global alliance and investigator-initiated clinical studies evaluating Celgene's investigational and approved therapies will be presented at the 61st American...
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
Shares of pharmaceutical giant Celgene slip after receiving a downgrade from analysts at Baird, despite posting better-than-expected quarterly results.
Celgene Corporation (NASDAQ: CELG) reported third quarter 2019 total revenue of $4,520 million, a 16 percent increase compared to $3,892 million in the third quarter of 2018.
U.S. stock futures are falling following a report that said Chinese officials have doubts about reaching a comprehensive long-term trade agreement with the United States; Apple and Facebook rise after posting better-than-expected earnings; Fiat Chrysler confirms it agreed to merger with France's Peugeot.
Traders can learn from watching, as well as doing, and with the FOMC meeting landing, now's best time to practice the former.
These stocks are priced for total imperfection. That's just what you want.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
The MS MindShift: A New View of MS initiative from Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) is making its third stop at the Owl-O-Ween Hot Air Balloon Festival in Kennesaw, Ga.
Jim Cramer weighs in on Raytheon, United Technologies, Yeti, Bristol-Myers Squibb, Mosaic, Square, JBG Smith Properties, Encana, BP, Waste Management.
Jim Cramer says it's going to take longer than most people think to reach a trade deal with China. He's got your game plan for next week.
Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity building in resource-constrained countries around the...
Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms of multiple sclerosis (RMS), at the 35 th Congress of...
Stocks finished higher Monday after President Donald Trump claims China contacted U.S. trade officials and said 'let's get back to' the negotiating table.
Jim Cramer breaks down Amgen's deal to buy Otezla's rights from Celgene.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Jim Cramer's breaking down his thoughts on pajama trading, and the U.S.-China trade war.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Jim Cramer weighs in on the U.S.-China trade war and Amgen.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.